Skip to content
OpenCapital
Get started

ADMA Biologics ADMA Nontaxable or nondeductible items

Nontaxable or nondeductible items at other companies

Zymeworks logo
ZymeworksZYME
-0.2%—

Other financials

Income statement

See full
Revenue$114.5M-0.3%
Gross profit$80.8M+32.2%
Operating income$58.3M+67.1%
Net income$45.3M+68.5%
EPS (diluted)$0.19+72.7%

Balance sheet

See full
Cash & equivalents$138.2M+92.9%
Total debt$204.4M+2,055%
Total equity$390.3M+4.5%
Total assets$665.2M+30.3%

Cash flow

See full
Operating cash flow$58.2M+396%
CapEx$2.5M-45.9%
Free cash flow$55.7M+329%

Valuation

See full
Market cap$2.01B-54.5%
Enterprise value$2.08B-52.5%
P/E12.2×-9.2×
P/S4×-5.7×

Profitability

See full
Gross margin61.3%+8.7pp
Operating margin42.1%+9.0pp
Net margin32.4%-12.6pp
FCF margin21.2%+1.4pp

Returns & leverage

See full
Return on equity43.3%-35.2pp
Debt / equity0.5×+0.5×
Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense.

The official record: ADMA Biologics’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's nontaxable or nondeductible items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ADMA Biologics's nontaxable or nondeductible items?
ADMA Biologics (ADMA) reported nontaxable or nondeductible items of 1.5% in Q4 2025.
What does nontaxable or nondeductible items mean?
The percentage point impact on the effective tax rate caused by expenses that are not deductible for tax purposes. This metric helps investors identify the drag on tax efficiency caused by specific non-deductible corporate expenditures.